Showing 1521-1530 of 1685 results for "".
- EyePoint Pharmaceuticals Forms Executive Scientific Advisory Boardhttps://modernod.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital. Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. B
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- EyeCare Partners Announces Completion of Six New Practice Acquisitions in Second Quarterhttps://modernod.com/news/eyecare-partners-announces-completion-of-six-new-practice-acquisitions-in-second-quarter/2478055/EyeCare Partners (ECP) announced the acquisition of six new optometry, ophthalmology and eye surgery centers in regional markets around the country. ECP closed on the following acquisitions during the second quarter: Vitreous Retina Macula Specialists of New Jersey in Somerset, New J
- New Retina Radio: Experts Discuss New Patient Protocols in COVID-19 Erahttps://modernod.com/news/new-retina-radio-experts-discuss-new-patient-protocols-in-covid-19-era/2477501/New Retina Radio has launched a new series covering the COVID-19 crisis featuring retina specialists around the world talking about how their practices have been affected. In the first episode of this series, host John W. Kitchens, MD, was j
- New Podcast Addresses COVID-19 Impacthttps://modernod.com/news/new-podcast-addresses-covid-19-impact/2477431/In the latest installment of the Off the Grid podcast, titled “Unprecedented Times,” cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, speak with Steven J. Dell, MD, and Tal Raviv, MD, to discuss the novel coronavirus and its impact on their respective states, practices, and dail
- Statins, Fibrates Lower Diabetic Retinopathy Risks in Diabeteshttps://modernod.com/news/statins-fibrates-lower-diabetic-retinopathy-risks-in-diabetes/2479824/The use of lipid-lowering medication with fibrates, including fenofibrate (Lipidil, Abbott), and statins reduces not only the incidence of diabetic retinopathy in patients with type 2 diabetes but also the need for treatment in those who already have the condition, indicates a real-world J
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT